Medical network - on March 22, lung cancer is one of the most common malignant tumor in our country, in 2012 global cancer statistics, lung cancer incidence of a disease accounted for 1.8 million cases, accounting for 13% of all cancer incidence of a disease. By 2016 that figure jumped to 27%. In China, 2015 new cases of lung cancer is more than 730000 people, the deaths of more than 610000 people, is the cause of cancer deaths.
Lung cancer targeted drug has been because of expensive for many patients, some patients can only be desperate to buy "contraband", or even dispensed on their own.
As market competition intensifies, the phenomenon in gradually improve. Announced a few days ago, boehringer ingelheim tumor targeting drug Afatinib (afar on behalf of, Chinese commodity name, terry) for imported drug registration certificate issued by the CFDA. This is the first time China has approved the second generation of lung targeting drugs, for the first time in nearly five years the listing of lung cancer drug approved in China.
, chairman of the China society of clinical oncology, guangdong lung cancer institute Wu Yilong told reporters: "as a result of chemotherapy in ACTS on the cancer cells as well as the effect on normal cells, inevitably bring. The side effects of larger compared with chemotherapy, targeted drug efficacy and safety is better. But the price is expensive, and is more important is to improve the early detection of lung cancer."
Today, Chinese competition in the field of lung targeting drug prices in the market situation, astrazeneca, roche pharmaceutical giant has halved drug pricing, etc. Last month, qilu pharmaceutical introduced domestic the treatment of lung targeting drug, further intensified market competition.
First China market "ticket"
Afar for, at the same time in the domestic approved two indications: for the epidermal growth factor receptor (EGFR) mutations positive first-line treatment in patients with lung cancer, as well as second-line treatment in patients with lung squamous carcinoma. Previously, the method for had approved in more than seventy countries and regions, including Taiwan, Hong Kong and Macao.
Boehringer ingelheim Chinese specialty products division director Stephen Doyle said: "we listed in China for more than a dozen products, such as breathing, stroke, diabetes, etc., the method for, in China's listed marks boehringer ingelheim officially entered the field of Chinese antitumor."
Lung cancer is one of the most common malignant tumor in our country, in 2012 the global cancer statistics, the incidence of lung cancer accounted for 1.8 million cases, accounting for 13% of all cancer incidence of a disease. By 2016 that figure jumped to 27%. In China, 2015 new cases of lung cancer is more than 730000 people, the deaths of more than 610000 people, is the cause of cancer deaths.
Wu Yilong tells a reporter, one of the pathogenic risk factors for lung cancer is smoking, belong to the relationship. Air pollution also has become a major reason that three years ago, the world health organization official PM2.5 in the lung cancer risk factors, the dangerous degree is equivalent to smoking.
"Lung cancer treatment depends on two things today, we need to get the molecular pathology testing, to see what genetic abnormality, according to the genetic abnormality to choose targeted therapy, make advanced non-small cell lung cancer patients live longer, we can gradually make advanced non-small cell lung cancer has become a chronic disease." Wu Yilong said.
Before the advent of lung targeting drugs, for early lung cancer patients with comprehensive treatment, including surgery, patients with advanced non-small cell lung cancer is given priority to with chemotherapy. However, because of its role in cancer chemotherapy also effect on normal cells, inevitably bring the side effects of larger, also increase the patient's pain.
With increasing understanding of genetics, medicine found that cancer is associated with certain genetic mutations, including EGFR receptors and other three ErbB family is out of control, is associated with the occurrence and deterioration of several common types of cancer, including lung cancer.
Thus, EGFR - TKI is becoming a hot spot of advanced non-small cell lung cancer treatment, was first approved drugs for the treatment is, it's TKI represented by generation. But generation only TKI drugs to inhibit the action of the EGFR, and with the combination of EGFR is reversible, the deterioration will be shown after the drug 10 months or so.
For he is the second generation TKI "method, with the difference between generation is not reversible." Wu Yilong tells a reporter, "o method for listed equals to the doctor's clinical treatment more than a choice. The treatment for the side effect is lower than the second generation of, for a very beautiful and patients may be a generation of drugs is better. But the second generation curative effect is stable, we choose the second generation for the young."
Price for quantity
Lung cancer targeted drugs battle for the Chinese market has fought for years.
Last year, Shanghai roche pharmaceuticals co., LTD. Announced its product it for a 30% cut. For, before the price, it sells for 4600 yuan/box (7), patients need to use more than four boxes on a monthly basis. This means, the use of the drug in patients, need to spend more than 18400 yuan a month. After a 30% cut, still need to spend 12880 yuan a month.
Earlier than tarceva is another important reduction the treatment drug, produced by astrazeneca pharmaceutical co., LTD., reduction of about 55%, from a carton 5000 yuan straight down to 2358 yuan. Last month, the qilu pharmaceutical announced that its production of domestic listed on the treatment of lung targeting drug, on the premise of consistent with the original drug quality, its price lower than after the price of the original medicine about a third.
Hospital management, tsinghua university, a researcher at skill analysis points out: "the previous price is too high, now the price is a rational regression. This brings to the enterprise reality effect is the sales volume, the future price will continue to drop, but time will grow a little."
Another for patients to see hope signal is, lung cancer targeted drugs are gradually into the Chinese health care.
In the recently released the 2017 edition of national health insurance directory, beida pharmaceutical (69.850, 0.00, 0.00%) for ek and astrazeneca, first in the treatment of drug directory. Before this, many provinces and cities also to proceed to lung cancer targeted drugs into the local health care, such as hunan province last year will be the treatment of astrazeneca in hunan province town worker medical treatment of a serious illness and mutual assistance and urban and rural residents of a serious illness insurance to pay limits.
Stephen Doyle told reporters: "at present in so many changes in the market. We have got the approval, then there's the customs, sample test, no later than July afar for, should be able to market in China. We will think of some way to see afar for he can go on to the provincial health insurance directory."
Although there are more and more lung cancer targeted drug into the Chinese market, drug prices also gradually rational return, but lung cancer treatment is still challenge.
Thoracic hospital affiliated to Shanghai jiaotong university, lung tumor, director of the center for clinical medicine Liu Shun pointed out that at present there are two of the biggest challenges: lung cancer treatment is a patient too early. In all of the diagnosis of lung cancer, 50% are advanced lung cancer patients. Second, Chinese drugs listed speed is still too slow.
Wu Yilong said: "to list in China of a drug is indeed very difficult, the method for an earlier start clinical trials in China, but it's only approved for drug approval too slow. In fact by low-dose spiral CT, check once a year can put the small one cm tumor found out. But few Chinese will take the initiative to go to a hospital checking, so early detection rate is very low."
Drug-resistant problem also needs to be overcome. Jilin province tumor hospital Cheng Ying say: "from one generation to the second generation of now, good treatment could be a period of time appear some resistant or some secondary resistance or primary drug resistance. We are also want to strategy, including the combination therapy, we are now doing what we are doing TKI and the combination of chemotherapy, and the second generation or third generation of drugs used in a line to overcome the primary drug resistance." |
